摘要
To the Editor:Psoriasis is a chronic inflammatory proliferative disease mediated by T lymphocytes under a multi-gene genetic background.[1]Moreover,its pathogenesis is not fully understood.Recent research shows that T cell-mediated immune inflammation plays a key role in the pathophysiology of psoriasis,and its most common downstream mediator,interleukin(IL)-17,is the primary effector cytokine in this condition.Secukinumab is a high-affinitive,fully humanized,G1κmonoclonal antibody that can simultaneously block IL-17A from multiple sources.[2]In a global,core,phase III trial,secukinumab was confirmed to rapidly improve psoriasis symptoms;however,the efficacy of its use in Chinese population remains unknown.This study was performed in a Chinese population for a period of 16 weeks to explore the efficacy and safety of secukinumab after its introduction in clinical settings in May 2019.
基金
supported by a grant from the Guangzhou Medical and Health Technology General Guidance Project (20171A011285)。
